{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:54:44Z","timestamp":1791071684403,"version":"4.1.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2011,9,12]],"date-time":"2011-09-12T00:00:00Z","timestamp":1315785600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0024517","type":"journal-article","created":{"date-parts":[[2011,9,12]],"date-time":"2011-09-12T17:26:56Z","timestamp":1315848416000},"page":"e24517","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":39,"title":["Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial"],"prefix":"10.1371","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct00384787","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Beryl A.","family":"Koblin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Casapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixue Maggie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier D.","family":"Defawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Goepfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Juliana","family":"McElrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuen-Yen","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barney S.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The NIAID HIV Vaccine Trials Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,9,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nature07352","article-title":"Challenges in the development of an HIV-1 vaccine.","volume":"455","author":"DH Barouch","year":"2008","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1128\/9781555818012","article-title":"Immunology, Immunopathology and Immunity","author":"S Sell","year":"2001"},{"key":"ref3","article-title":"Skin Immune System","author":"JD Bos","year":"1997"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ni762","article-title":"Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo.","volume":"3","author":"CC Norbury","year":"2002","journal-title":"Nat Immunol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S1046-2023(03)00137-3","article-title":"Immunization with DNA through the skin.","volume":"31","author":"KK Peachman","year":"2003","journal-title":"Methods"},{"key":"ref6","first-page":"209","article-title":"Epidermal Langerhans cells: from neurons to nature's adjuvants.","volume":"14","author":"T Jakob","year":"1999","journal-title":"Adv Dermatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa043540","article-title":"Dose sparing with intradermal injection of influenza vaccine.","volume":"351","author":"RT Kenney","year":"2004","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa043555","article-title":"Serum antibody responses after intradermal vaccination against influenza.","volume":"351","author":"RB Belshe","year":"2004","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1023\/B:EJEP.0000040532.99890.9f","article-title":"High seroprotection rate induced by intradermal administration of a recombinant hepatitis B vaccine in young healthy adults: comparison with standard intramuscular vaccination.","volume":"19","author":"MJ Ghabouli","year":"2004","journal-title":"Eur J Epidemiol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1708-8305.2009.00351.x","article-title":"Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration.","volume":"16","author":"G Frosner","year":"2009","journal-title":"J Travel Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1086\/651561","article-title":"Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.","volume":"201","author":"MB Wilck","year":"2010","journal-title":"J Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"7304","DOI":"10.1016\/j.vaccine.2009.10.033","article-title":"Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.","volume":"27","author":"R Arnou","year":"2009","journal-title":"Vaccine"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0264-410X(01)00462-5","article-title":"Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans.","volume":"20","author":"PR Pittman","year":"2002","journal-title":"Vaccine"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1086\/317553","article-title":"Choosing a route of administration for quadrivalent meningococcal polysaccharide vaccine: intramuscular versus subcutaneous.","volume":"32","author":"FL Ruben","year":"2001","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1086\/501756","article-title":"Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers.","volume":"21","author":"EA Henderson","year":"2000","journal-title":"Infect Control Hosp Epidemiol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/509258","article-title":"Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.","volume":"194","author":"AT Catanzaro","year":"2006","journal-title":"J Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1016\/j.vaccine.2007.02.050","article-title":"Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.","volume":"25","author":"AT Catanzaro","year":"2007","journal-title":"Vaccine"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e9015","DOI":"10.1371\/journal.pone.0009015","article-title":"Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.","volume":"5","author":"RA Koup","year":"2010","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.","volume":"372","author":"SP Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.4049\/jimmunol.172.10.6290","article-title":"Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.","volume":"172","author":"DH Barouch","year":"2004","journal-title":"J Immunol"},{"key":"ref21","article-title":"International seroprevalence of neutralizing antibodies against adenoviral serotypes 5 and 35.","author":"C Morgan","year":"2005"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.vaccine.2006.07.050","article-title":"Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.","volume":"25","author":"PA Goepfert","year":"2007","journal-title":"Vaccine"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.","volume":"82","author":"GD Tomaras","year":"2008","journal-title":"J Virol"},{"key":"ref24","first-page":"12.11.1","article-title":"Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays.","author":"DC Montefiori","year":"2004"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","article-title":"Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.","volume":"79","author":"M Li","year":"2005","journal-title":"J Virol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/QAI.0b013e3180377b5b","article-title":"Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay.","volume":"45","author":"S Dubey","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1016\/j.vaccine.2006.06.009","article-title":"Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation.","volume":"24","author":"F Li","year":"2006","journal-title":"Vaccine"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jim.2006.07.015","article-title":"Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials.","volume":"315","author":"Z Moodie","year":"2006","journal-title":"J Immunol Methods"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jim.2007.03.002","article-title":"Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination.","volume":"323","author":"H Horton","year":"2007","journal-title":"J Immunol Methods"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cyto.a.20600","article-title":"Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials.","volume":"73","author":"N Shulman","year":"2008","journal-title":"Cytometry A"},{"key":"ref31","article-title":"Questions and Answers: The HVTN 505 HIV Vaccine Regimen Study.","year":"2010"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e12873","DOI":"10.1371\/journal.pone.0012873","article-title":"Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.","volume":"5","author":"W Jaoko","year":"2010","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1086\/650299","article-title":"A phase 1\/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).","volume":"201","author":"H Kibuuka","year":"2010","journal-title":"J Infect Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"e13579","DOI":"10.1371\/journal.pone.0013579","article-title":"Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).","volume":"5","author":"L Peiperl","year":"2010","journal-title":"PLoS One"},{"key":"ref35","article-title":"Ongoing development and evaluation of a potential HIV-1 vaccine using a replication-defective adenoviral vector.","author":"EA Emini","year":"2003"},{"key":"ref36","article-title":"A potential HIV-1 vaccine using a replication-defective adenoviral vaccine vector.","author":"EA Emini","year":"2002"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1128\/JVI.00068-08","article-title":"Multifunctional T-cell characteristics induced by a polyvalent DNA prime\/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration.","volume":"82","author":"A Bansal","year":"2008","journal-title":"J Virol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"e725","DOI":"10.1371\/journal.pone.0000725","article-title":"Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial.","volume":"2","author":"O Launay","year":"2007","journal-title":"PLoS One"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1086\/509259","article-title":"Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.","volume":"194","author":"BS Graham","year":"2006","journal-title":"J Infect Dis"},{"key":"ref40","author":"C Morgan","year":"2007"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0024517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T09:04:06Z","timestamp":1638608646000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0024517"}},"subtitle":[],"editor":[{"given":"Shan","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,9,12]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,9,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0024517","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,12]]}}}